Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Great Basin Announces Conversion of Remaining Series C Warrants Company reports 75.5 million shares of Common Stock Issued and Outstanding Salt Lake City, January 21, 2016 - Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today that as of 5 p.m. the Company has converted all outstanding Series C Warrants into shares of its common stock and therefore now has 75.5 million shares of common stock issued and outstanding, and has no remaining unconverted Series C Warrants. Today, January 21, 2016, Great Basin converted the remaining 1,221,587 Series C Warrants. It settled 1,416 warrants with cash and settled the remainder by issuing 13.7 million shares of Great Basin common stock. The Company did not issue any of the Pre-funded Rights to acquire its common stock. Please see Exhibit A for a detailed capitalization table, which reflects the Company’s capitalization as of 5 p.m., January 21st. Shares of common stock will be delivered to Series C warrant holders when the warrant holder surrenders his or her Series C warrants along with a completed Series C Warrant mandatory exercise form which is available on the Company’s website at http://client.irwebkit.com/gbscience. About Great Basin Scientific Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. Forward-Looking Statements This press release includes forward-looking statements regarding the exercise and exchange of Series C warrants, the Company having sufficient authorized, unreserved and unissued shares to settle all Series C warrants upon mandatory conversion, and the potential issuance of prefunded rights upon mandatory conversion of the Series C Warrants. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law. The shares of common stock and pre-funded rights issuable upon exercise of the Series C Warrants have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or any applicable state securities laws and may not be offered or sold absent such registration or pursuant to an available exemption from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. Exhibit A Capitalization Table January 21, 2016 (in million of shares) Authorized Shares 200 Common Stock Issued and Outstanding* 75.5 Pre-funded Rights to Acquire Common Stock 0 TOTAL Shares Outstanding (including pre-paid rights) 75.5 Shares Reserved for Convertible Note Holders and Related Derivatives 120 Shares Reserved for Other Derivatives, including Series E Preferred Stock 0.2 Unreserved and Unissued Shares 4.3 Series C Warrants 0 Series E Convertible Preferred Stock** 0.1 * Includes approximately 1 million shares of common stock to be delivered upon the surrender the 92,069 converted Series C Warrants that remain to be surrendered as of this date th **Each share of Series E Convertible Preferred Stock is convertible into 4/60 of one share of common stock—were all Series E Convertible Preferred Stock to be converted into common shares, the Company would issue 5,890 shares of its common stock to the holders of the Series E Convertible Preferred Stock. Media Contact: Kate Ottavio Kent ICR 203.682.8276 [email protected] Investor Relations Contact: David Clair ICR 646.277.1266 [email protected] ###